Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,960 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,960 Papers indexed
963 Papers AI scored
37,960 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37960 results
B
Neurobehavioral outcomes and associated risk factors in pediatric brain tumor survivors.
PMID 41964753 Published: 2026-04-11 Ingested: 2026-08-02 12:06 AM Journal of neuro-oncology
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.0; sample size: 70.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 83.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.
PMID 40622633 Published: 2025-07-07 Ingested: 2026-08-02 12:04 AM Reviews in endocrine & metabolic disorders
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Gonadal function in pediatric female post-Allo-HSCT: a real-life prospective study from China.
PMID 40553563 Published: 2025-06-24 Ingested: 2026-08-02 12:04 AM Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 28.0; sample size: 60.0; recency: 90.0; abstract quality: 85.0.

B
Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions.
PMID 40550858 Published: 2025-06-23 Ingested: 2026-08-02 12:04 AM Cancer immunology, immunotherapy : CII
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 95.5; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Implementing Evidence-Based Strategies to Improve Pediatric Oncology Infection Management.
PMID 40446180 Published: 2025-05-30 Ingested: 2026-08-02 12:04 AM American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 28.0; sample size: 60.0; recency: 90.0; abstract quality: 85.0.

B
Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase.
PMID 40302153 Published: 2025-04-29 Ingested: 2026-08-02 12:04 AM Clinical pharmacology and therapeutics
AI -
Base 72.1
Rank 72.1
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 28.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Previous
Page 486 of 3164
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic